Background: Hispanics in the US have a lower age-adjusted mortality in NSCLC and may have a different gene expression profile than NHWs. Additional data is thus needed to validate outcomes in Hispanic patients with NSCLC treated with ICIs. Our aim was to compare clinical outcomes between Hispanic and NHW patients with advanced NSCLC treated with ICIs at 5 large institutions in the US and Latin America. Method: Retrospective clinical review on 436 Hispanic pts with advanced NSCLC that had failed at least one prior line of chemotherapy or were treated with single-agent immunotherapy as first line. Pts with actionable genetic aberrations (EGFR, ALK, and ROS-1) were excluded. Primary endpoints assessed were OS, PFS, and ORR (CR+PR) while secondary endpoint was DCR (ORR+SD). Results: Patient characteristics are summarized in table 1. Primary endpoint results are summarized in table 2. There were no statistical significant differences seen in the secondary endpoint (DCR) among Hispanics and NHW pts. Conclusion: No significant differences were found in the clinical outcomes between Hispanic and NHW patients despite expected genomic differences. As expected, higher response rates were seen in first line therapy and patients with PD-L1 (+) status. These findings validate efforts in making immunotherapy more available to Hispanic patients worldwide.

No abstract

No abstract

No abstract